A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

Inclusion Criteria

• •Men and women aged 18 years to 50 years (inclusive)
• •Diagnosis of asthma (GINA 2011) including a demonstration of reversible airway obstruction
• •Pre-bronchodilator FEV1 value ≥ 40% and ≤ 85% of the predicted normal value at baseline
• •A score of 1.5 or greater on the Asthma Control Questionnaire at baseline
• •Daily use of low to moderate dose of ICS (equivalent to budesonide ≤ 800 µg per day)
• •Prescribed a short-acting inhaled bronchodilator as reliever therapy for relief of symptoms
• •A peripheral blood eosinophil count ≥ 0.25 x 109/L
• •Non-smoker or former smoker who has not smoked in the last six months
• •Body mass index (BMI) ≥ 17 and ≤ 35 kg/m2
• •Able to comply with the protocol requirements, instructions and restrictions
• •Able to provide signed and dated written informed consent